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Abstract
Visceral leishmaniasis (VL), caused by the intracellular parasite Leishmania donovani is a major public health problem in the
developing world. But there is no effective and safe vaccine approved for clinical use against any form of leishmaniasis.
Through reactivity with kala-azar patient and cured sera, polypeptides ranging from 91 to 31-kDa from L. donovani
promastigotes were previously identified as potential protective vaccine candidates. In this study four polypeptides
91(LD91), 72 (LD72), 51(LD51) and 31 (LD31)-kDa were purified using sodium dodecyl sulfate polyacrylamide gel
electrophoresis followed by electroelution. We compared the vaccine efficacy of these antigens encapsulated in cationic
liposomes in BALB/c mice against challenge infection with L. donovani. Our results demonstrated that liposomal LD31 (74%–
77%) and LD51 (72%–75%) vaccination reduced parasite burden to the greatest degree followed by liposomal LD72 (65%–
67%) and LD91 (46%–49%). Analysis of the cytokine responses in immunized mice revealed that all the vaccinated groups
produced prechallenge interferon-c, interleukin-12 and interleukin-4. Interestingly, the degree of reduction in parasite load
could be predicted by the magnitude of the cytokine responses which correlated inversely with the parasite burden both in
liver and spleen. The 31, 51 and 72-kDa bands were identified as ATP synthase a chain, b-tubulin and heat shock 70-related
protein 1 precursor of L. major, respectively using matrix-assisted laser desorption ionization–time of flight (MALDI-TOF/
TOF) mass spectrometry. These three leishmanial antigens have not been described before as successful vaccine candidates
examined against in vivo VL model. Thus, these antigens can be potential components of future antileishmaniasis vaccines.
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Introduction
Leishmaniasis is a vector-transmitted disease distributed world-
wide mainly in the tropical and subtropical countries. At least 20
Leishmania species can give rise to a wide spectrum of clinical
manifestations, ranging from self-healing cutaneous lesions to
visceral leishmaniasis (VL), the latter being an invariably fatal
disease in the absence of drug treatment. Moreover, Leishmania is
emerging as important opportunistic pathogen in persons
coinfected with human immunodeficiency virus. Therapeutic
options for controlling leishmaniasis are limited to a few drugs
with inconsistent efficacy and side effects. Thus, there is an urgent
need to develop a safe and effective Leishmania vaccine to help
prevent the two million new cases of leishmaniasis worldwide each
year [1].
Recent progress to design vaccines against leishmaniasis is based
on molecularly defined antigens, the so-called second-generation
vaccines. The availability of the complete L. major and L. infantum
genome sequence may lead to identification of genes responsible
for the different disease phenotypes [2], but vaccine candidates will
probably be harder to pinpoint in the genome because without
knowing the function of a pathogen protein its protective potential
is not guaranteed [3]. A large number of leishmanial antigens
against experimental leishmaniasis have been attempted for
vaccination, mainly against the cutaneous form. There are also
reports of defined antigens protective against VL in animal models
such as KMP11, HASPB, A2, ORFF and CPB [4–8]. However
there is still only a little progress and a limited number of potential
candidates to combat this disease through vaccination [9].
Moreover, proteins identified from cutaneous form when tested
against challenge infection with L. donovani in experimental models
have found to be either partially protective or unsuccessful [10–
12]. Thus there is a need for identifying new antigens from L.
donovani ideally relying on correlates of protective immunity.
Several studies of L. major support that resistance towards
infection is linked to the ability to mount a Th1 response which
leads to the activation of macrophages for elimination of the
obligatory intracellular parasite [13]. Protective immunity in L.
donovani is also dependent on an IL-12 driven Th1 and IFN-c
production [14,15]. However, an exclusive generation of a
vaccine-induced Th1 is insufficient to ensure protection and
cannot be a predictor of vaccine success in experimental VL
[10,16]. In murine cutaneous leishmaniasis (CL) a Th2 response
and IL-4 production have been associated with chronic infection
[13]. Although induction of IL-4 in infected BALB/c and
noncuring models [17,15] has been observed, beneficial roles of
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IL-4 have also been described for L. donovani resistance [18].
Moreover, recent studies in CL indicate that induction of high
levels of the regulatory cytokine IL-10 can cause vaccine failure
even in the presence of high levels of IFN-c [19]. Thus, one of the
biggest challenges for development of a vaccine against VL is to
unravel the prechallenge predictor for vaccine success.
Our prior observations demonstrated that antigens of L. donovani
promastigotes (LAg) in cationic liposomes could significantly reduce
parasite load in BALB/c mice and hamsters after challenge
infection [20]. We also found that LAg had strong serologic
reactivity with Indian VL patient sera. While dissecting the humoral
immune responses to the dominant components of LAg by Western
blot analysis, we found that polypeptides with molecular masses of
31, 34, 51, 63, 72 and 91-kDa were reactive with all the kala-azar
patients’ sera prior to treatment. Although after successful treatment
with sodium antimony gluconate (SAG) decreases in the frequency
of recognition and the intensities of bands were observed, the bands
were still reactive with posttreatment sera with high frequencies
ranging from 73% to 100% [21]. These observations provide an
insight into the vaccine potential of these antigens. Our previous
report demonstrated that 63-kDa antigen entrapped in cationic
liposomes induced reduction in parasite burden in BALB/c mice
[22], and liposomal 34-kDa antigen was found to be ineffective to
reduce parasite level in the same murine model (unpublished
observation). Thus, in the present study we purified and identified
the remaining four polypeptides of approximately 91, 72, 51 and
31-kDa and compared the challenge outcome with L. donovani and
immune responses in BALB/c mice to identify key immunological
correlates of protection in VL.
Methods
Animals and parasites
BALB/c mice, bred in the Institute animal facility (Kolkata,
India), were 4–6 weeks old at the onset of the experiments. The
studies were approved by IICB Animal Ethical Committee and
mice were handled according to their guidelines. L. donovani strain
AG83 (MHOM/IN/1983/AG83) promastigotes were grown at
22uC in Medium 199 supplemented with penicillin G sodium
(l00 U/ml), streptomycin sulfate (100 mg/ml) and 10% heat
inactivated fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis,
MO) and subcultured in the same medium at an average density of
26106 cells/ml [20].
Preparation of antigens
Leishmanial antigens (LAg) were prepared from L. donovani
promastigotes as described earlier [20]. Briefly, stationary-phase
promastigotes, harvested after the third or fourth passage, were
washed three times in cold 20 mM phosphate-buffered saline
(PBS), pH 7.2, and resuspended at a concentration of 1.0 g of cell
pellet in 50 ml of cold 5 mM Tris-HCl buffer, pH 7.6. The
suspension was vortexed and centrifuged at 2,3106g for 10 min.
The crude ghost membrane pellet thus obtained was resuspended
in the same Tris buffer and sonicated for 3 min by ultrasound
probe sonicator (Misonix, Farmingdale, NY). The suspension was
centrifuged at 5,1906g for 30 min, and the supernatant
containing the leishmanial antigens was harvested and stored at
270uC until use. The amount of protein obtained from a 1.0-g cell
pellet, as assayed by the method of Lowry et al. [23], was
approximately 10 mg.
SDS-PAGE and electroelution
The LAg was subjected to sodium dodecyl sulfate–10%
polyacrylamide gel electrophoresis (SDS–10% PAGE) by the
method of Laemmli et al., 1970 [24] and stained with Coomassie
blue. The proteins with molecular mass of 91, 72, 51 and 31-kDa
were eluted by electrophoresis in running buffer (0.025 M Tris,
0.192 M glycine, 1% SDS) using a Electro-Eluter (model 422; Bio-
Rad) at 10 mA for 5 h. After elution, the proteins were dialyzed,
lyophilized and resuspended in PBS. Proteins were further
visualized by SDS-PAGE and silver staining [25]. The proteins
were quantified by Lowry’s method [23].
Entrapment of antigens in liposomes
Cationic liposomes were prepared with distearoyl phosphati-
dylcholine (DSPC) (27 mmole), cholesterol (Sigma-Aldrich) and
stearylamine (Fluka, Buchs, Switzerland) at a molar ratio of 7:2:2
as described previously [22]. Empty and antigen entrapped
liposomes were prepared by the dispersion of lipid film in either
1 ml PBS alone or containing 200 mg/ml antigen respectively.
The mixture was vortexed and the suspension sonicated for 30 sec
by an ultrasound probe sonicator (Misonix). Liposomes with
entrapped antigens were separated from excess free antigen by
three successive washing in PBS with ultracentrifugation
(105,0006g, 60 min, 4uC) [25]. The encapsulation efficiency was
determined by the method of Lowry et al., in the presence of 10%
SDS [23]. The level of encapsulation ranged between 50 to 60%.
Immunization of mice and challenge infection
The experimental groups consisted of 4–6 weeks old BALB/c
mice. Mice were immunized by intraperitoneal injections of 2.5 mg
purified proteins in PBS or incorporated in liposome in a total
volume of 200 ml. Animals receiving PBS or empty liposomes
served as controls. Mice were boosted two times at 2-week
intervals. Ten days after the last booster, serum samples were
collected, and spleens were removed aseptically for the analysis of
humoral and cellular responses after immunization. Ten days after
the final immunization rest of the mice were challenged with
2.56107 freshly transformed stationary-phase promastigotes in
200 ml PBS injected intravenously via the tail vein as described
earlier [20,22]. After 3 months of challenge infection, the mice
were sacrificed to determine the parasite load in liver and spleen
[22]. The course of infection was monitored by the microscopic
examination of Giemsa-stained impression smears of liver and
spleen. The parasite load was expressed as Leishman-Donovan
units and was calculated by the following formula: number of
amastigotes per 1000 cell nuclei6organ weight (mg) [26].
Assessment of delayed type hypersensitivity response
(DTH)
Delayed type hypersensitivity (DTH) was determined as an index
of cell mediated immunity. The response was evaluated by measuring
the difference in the footpad swelling at 24 h following intradermal
inoculation of the test footpad with 50 ml of LAg (800 mg/ml) and the
swelling of the control (PBS injected) footpad with a constant pressure
caliper (Starrett Company, Athol, MA) [20].
Cell proliferation and cytokine assays
The spleens were aseptically removed from the immunized and
infected BALB/c mice and single cell suspensions were prepared
in RPMI 1640 supplemented with 10% FBS, l00 U/ml penicillin
G sodium, 100 mg/ml streptomycin sulfate and 50 mM b-
mercaptoethanol (Sigma-Aldrich) (complete medium). RBCs were
removed by lysis with 0.14 M Tris buffered NH4Cl. The
remaining cells were washed twice with culture medium and
viable mononuclear cell number was determined by counting
Trypan blue unstained cells in a hemocytometer. Then the cells
Novel Antigens of L. donovani
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were cultured in triplicate in a 96 well flat bottom plate (Nunc,
Roskilde, Denmark) at a density of 26105 cells/well in a final
volume of 200 ml complete medium and stimulated with antigens
(2.5 mg/ml). The cells were incubated for 96 h at 37uC in a
humified chamber containing 5% CO2. Cells were pulsed with
1 mCi of [3H ]-Thymidine (Amersham Biosciences, Buckingham-
shire, UK) per well 18 h before they were harvested on glass fiber
paper. Thymidine uptake was measured in a b-scintillation
counter (Beckman Instruments, Fullerton, CA) [25]. After 72 h
incubation, culture supernatants were collected and the concen-
tration of IFN-c, IL-4, IL-12p40 and IL-10 (BD Pharmingen, San
Diego, CA) were quantitated by ELISA in accordance with the
manufacture’s instructions [27].
Determination of antibody response
Sera from immunized and infected animals were analyzed by
ELISA for the presence of antigen specific antibodies. In brief, 96-
well microtiter plates (Maxisorp, Nunc) were coated with antigens
(10 mg/ml) diluted in 20 mM phosphate buffer (pH 7.5) overnight
at 4uC. The plates were blocked with 1% BSA in PBS at room
temperature for 3 h to prevent nonspecific binding. After washing
with PBS containing 0.05% Tween 20 (Sigma-Aldrich) (PBST) the
plates were incubated overnight with 1:1000 dilution of mice sera
at 4uC. Next day, the plates were again washed with PBST and
incubated further for 3 h at room temperature with horseradish
peroxidase conjugated goat antimouse IgG1 and IgG2a (BD
Pharmingen) diluted 1:1000 in blocking buffer. The plates were
washed and substrate solution (o-phenylene diamine dihydrochlo-
ride, 0.8 mg/ml in 0.05 M phosphate-citrate buffer, pH 5.0,
containing 0.04% H2O2 ) (100 ml) was added for 30 min and the
absorbance was read in an ELISA plate reader (Thermo,
Waltham, MA) at 450 nm [20].
Mass spectrometry
Protein samples were separated by SDS-PAGE and visualized
with Coomassie blue or silver staining (ProteoSilverTM Plus silver
stain kit, Sigma-Aldrich). The in-gel digestion of proteins was
carried out according to the manufacturer’s manual (Pierce,
Rockford, IL). The desired band was excised and destained. The
possible disulfide bonds were reduced with tris (2-carboxyethyl)
phosphine (TCEP) and alkylated with iodoacetamide. Then the
gel pieces were dehydrated with acetonitrile and rehydrated with
100 ng trypsin (Promega, Madison, WI) in 25 mM ammonium
bicarbonate solution and were incubated at 37uC overnight. The
tryptic fragments were extracted from the gel by adding 1%
trifluroacetic acid. Then, the peptides were purified with C18
reversed-phase minicolumn filled in a micropipette tip, ZipTip
C18 (Millipore, Bedford, MA). Purified peptides (0.5 ml) were
cocrystallized with a-cyano-4-hydroxy cinnamic acid matrix
(0.5 ml) (Applied Biosystems, Foster City, CA) on a matrix-assisted
laser desorption ionization (MALDI) target plate. Both mass
spectrometry (MS) and MS/MS spectra were acquired by matrix-
assisted laser desorption ionization–time of flight (MALDI-TOF/
TOF) Mass Spectrometer (Applied Biosystems 4800 Proteomics
Analyzer). All spectra were collected in the reflector mode.
Calibration was updated before each acquisition using a standard
peptide mixture according to instrument protocol. Database
searching for protein identification was performed with mass
spectrometry data using GPS Explorer (Applied Biosystems)
software with MASCOT (Matrix Science) search engine.
N-terminal sequencing
The antigens were subjected to SDS-PAGE electrophoresis, and
electrotransferred onto a polyvinylidene difluoride membrane
(Immobilon P; Millipore) in 10 mM 3-[cyclohexylamino]-1-
propanesulfonic acid and 10% methanol, pH 11.0. The bands
on the membrane were excised after staining according to
manufacturer’s instructions. The N-terminal amino acid sequence
was determined by Edman degradation chemistry using a Procise
492 Protein sequencer (Applied Biosystems) [22].
Statistical analysis
One-way analysis of variance (ANOVA) and Tukey’s multiple
comparisons post-test were used for the analysis of parasite burden
and antibody response data using Graph Pad Prism version 4.0
(Graphpad Software, v. 4.0, San Diego, CA). The statistical analyses
for other experiments before and after infection were made by a
two-way ANOVA. Corrections to the level of significance were
done using Bonferroni’s method. Results with p,0.05 were
considered to be statistically significant. For correlation analysis,
all datasets were calculated for correlation efficiency and were
considered significant at p,0.05. Spearman’s rank correlation
coefficient values were evaluated and represented (r).
Results
Parasite burdens in vaccinated BALB/c mice after L.
donovani challenge infection
Proteins from LAg ranging from 91 to 31-kDa were purified by
eletroelution from 10% SDS-PAGE gel and then visualized on
SDS-PAGE followed with silver staining (Figure 1). BALB/c mice
were immunized intraperitoneally with antigens LD91 (91-kDa),
LD72 (72-kDa), LD51 (51-kDa) and LD31 (31-kDa) entrapped in
cationic liposomes as the adjuvant. The vaccination was repeated
twice at 2-week intervals and the mice were challenged
intravenously with L. donovani promastigotes 10 days after the
last immunization. Control mice were injected with the empty
liposomes or PBS. We and others have found that infection with
the Indian strain, L. donovani AG83 in BALB/c mice results in a
progressive infection in the liver and spleen, corresponding with
hepato and splenomegaly [22,27–30]. Mice were therefore
sacrificed after 3 months when parasite loads were well expressed
in both liver and spleen. In liver, the greatest degree of reduction
in parasite burden was observed in mice immunized with
liposomal LD31 (74%) followed by LD51 (72%) (Figure 2A).
Although immunization with liposomal LD31 induced higher
levels of reduction than liposomal LD51, the difference was not
statistically significant. Vaccination with liposomal LD72 (65%)
conferred reduction in parasite load to a moderate level.
Immunization with LD91 in liposomes (46%) also reduced parasite
load significantly in mice but to the lowest degree (p,0.001
compared to controls). In BALB/c mice persistence of L. donovani
in the spleen causes concomitant development of considerable
organ-specific pathology similar to that seen in the human kala-
azar. It was, therefore, important to evaluate the effect of
vaccination in this organ. Similar to liver, mice immunized with
liposomal LD31 (77%) and LD51 (75%) demonstrated highest
reduction in splenic parasite burden with a moderate level in mice
immunized with LD72 (67%) and lowest but significant level with
LD91 (49%, p,0.001 compared to controls) (Figure 2B). It may
be noted that the reduction in parasite burden by the different
liposomal antigens were maintained in both the organs.
DTH and splenocyte proliferative responses in vaccinated mice
before and after challenge infection DTH, an index of cell-
mediated immunity in vivo, and antigen induced proliferation of
splenocytes in vitro were evaluated in different vaccinated mice 10
days after the last immunization. Among the different vaccinated
groups, liposomal LD31 and LD51 immunized groups exhibited
Novel Antigens of L. donovani
PLoS ONE | www.plosone.org 3 June 2009 | Volume 4 | Issue 6 | e5820
the highest degree of both DTH (Figure 3A, p,0.0001) and
proliferative response of splenocytes (Figure 3B, p,0.0001)
compared to controls. Liposomal LD72 and LD91 also induced
considerably higher responses than controls (p,0.0001). Controls
exhibited almost similar level of splenocyte proliferation after
stimulation with different antigens. Stimulation with total LAg also
enhanced the proliferative response of the vaccinated groups but
lower in magnitude as observed with specific antigens (data not
shown). The responses were further measured after 3 months of L.
donovani infection. At this stage, all the groups of mice presented
increased DTH and proliferative responses, compared to their
respective levels before infection (p,0.001). Similar to prechal-
lenge, mice immunized with all four liposomal LD31, LD51,
LD72 and LD91 displayed enhanced but varying magnitudes of
both DTH and antigen-induced splenocytes proliferative respons-
es (p,0.0001 compared to controls) at 3 months post infection.
Cytokine responses in vaccinated mice before and after
challenge with L. donovani
Next, we analyzed different cytokine production by splenocyte
following restimulation with specific antigens in vaccinated mice.
Following immunization, different vaccinated groups produced
substantial amounts of IFN-c (Figure 4A), IL-12 (Figure 4B) and
IL-4 (Figure 4C) compared to controls (p,0.0001). There was no
difference in the cytokine production in control animals when
stimulated in vitro with different antigens. Both liposomal LD31
and LD51 secreted highest level of IFN-c and IL-12 compared to
controls (p,0.0001). Interestingly, these groups also secreted IL-4
in high magnitude (p,0.0001 compared to controls). Before
infection there was no stimulation of IL-10 production in any of
the vaccinated groups in response to antigens (Figure 4D).
Splenocytes of different vaccinated mice also secreted increased
amounts of IFN-c, IL-12 and IL-4 when stimulated with total LAg
but response was lower than with the specific antigens (data not
shown). Taken together, the quality of cytokine responses in
Figure 1. Silver-stained SDS-PAGE gel of Leishmanial antigens
(LAg) and purified antigens by electroelution. Lane 1, molecular
mass markers; lane 2, LAg ; lane 3, 91-kDa (LD91); lane 4, 72-kDa (LD72);
lane 5, 51-kDa (LD51); lane 6, 31-kDa (LD31). The positions of molecular
mass standards are shown on the left in kilodaltons.
doi:10.1371/journal.pone.0005820.g001
Figure 2. Parasite burdens in BALB/c mice vaccinated with cationic liposomal antigens after L. donovani challenge infection. Mice
were vaccinated intraperitoneally 3 times with 2.5 mg of each antigen entrapped in cationic liposomes at 2-week intervals. Control groups received
PBS or empty liposomes (Lip). At 10 days after the last immunization, the mice were challenged intravenously with 2.56107 promastigotes of L.
donovani. Liver (A) and spleen (B) parasite burden were measured 3 months after challenge as Leishman Donovan Units (LDU). The results are mean
LDU6S.E. of five individual mice per group, representative of two independent experiments with similar results. * p,0.001 in comparison to control
groups as assessed by one-way ANOVA and Tukey’s multiple comparison test.
doi:10.1371/journal.pone.0005820.g002
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different vaccine groups represented production of IFN-c, IL-12
and IL-4 before infection which correlated with the decreased
parasite level in post infection. In addition, these results suggested
a link between the magnitude of these cytokine responses and the
extent of reduction in parasite burden.
With progressive infection, levels of IFN-c and IL-12 remained
low although pronounced stimulation of IL-4 and IL-10 (p,0.001)
compared to the level before infection, were observed in the
supernatants from splenocytes of control infected mice stimulated
with different antigens. Splenocytes from mice immunized with
liposomal LD31, LD51 and LD72 secreted high levels of IFN-c
and IL-12 (p,0.0001 compared to controls) significantly
enhanced in comparison to prechallenge (p,0.001). Levels of
IL-4 and IL-10 remaind low (p,0.0001 compared to controls) in
these vaccinated groups with decreased parasite load. In contrast,
IFN-c and IL-12 levels were comparatively lower in LD91
immunized mice with higher levels of IL-4 and IL-10 production.
An increase, however was observed in the levels of all the cytokines
when compared to prechallenge response (p,0.001).
Production of IgG2a and IgG1 before infection is
predictive of successful vaccination
Because cytokines such as IFN-c and IL-4 direct immunoglobin
class switching for IgG2a and IgG1, respectively [31] we measured
antigen specific production of these antibody isotypes before
infection to provide an indirect but physiologic in vivo assessment
of the pattern of cytokine production and consequently reduction
of parasite load after challenge infection. Sera from mice
immunized with liposomal LD31 and LD51 contained elevated
and highest levels of both the IgG2a and IgG1 isotypes (Figure 5,
p,0.001 compared to controls), although the level of IgG2a was
higher than that of IgG1. Significant enhancement for both the
isotypes with a dominance of IgG2a were also observed in
liposomal LD72 immunized groups with minimum production of
the isotypes in liposomal LD91 group (p,0.001 compared to
controls) These results further substantiate the magnitude of the
production of both the cytokines, IFN-c and IL-4, before infection
is predictive of success of vaccination.
Assesment of immune correlates of protective immunity
Differences in the IFN-c, IL-12 and IL-4 production between
vaccine groups prompted us to evaluate the potential correlations
between the cytokine responses after immunization and parasite
burden in the vaccinated animals of the representative groups.
Importantly there was a strong inverse correlation between the
liver parasite burden and magnitude of the IFN-c production
before infection (Figure 6A). Also, the differential production of
IL-12 (Figure 6B) and IL-4 (Figure 6C) correlated with control of
infection, suggesting the identification of associates of reduced
parasite burden after immunization. A statistical correlation
between the cytokine responses and pathogenesis was then
determined in spleen. There was also a striking inverse correlation
between the IFN-c, IL-12 and IL-4 (Figure 6D to F) productions
and the parasite burden in spleen, signifying a direct correlation of
parasite burden with the magnitude of the cytokine responses after
immunization.
Identification of antigens which conferred protection
against challenge infection
Immunization with liposomal LD31, LD51 and LD72 exhibited
enhanced reduction in parasite burden with a preferable immune
response against L. donovani challenge. To identify these
candidate vaccine antigens, the bands were excised, subjected to
in-gel trypsin digestion. The digested proteins were analyzed by
MALDI-TOF/TOF mass spectrometry, and the MS and MS/MS
spectrum were searched against all the known Leishmania spp.
sequences in MSDB and NCBInr databases using MASCOT
search engine. LD31 was identified as ATP synthase a chain of L.
major (Table 1). The band of LD51 was identified as b-tubulin of
L. major. Again, the N-terminal sequence of LD51 found to be
Figure 3. DTH and splenocyte proliferation in BALB/c mice vaccinated with cationic liposomal antigens before and after challenge
infection. Ten days after the last vaccination and 3 months after challenge infection DTH (A) and splenocyte proliferative (B) responses were
measured. DTH response is expressed as the difference (in millimeters) between the thickness of the test (LAg-injected) and control (PBS-injected)
footpads at 24 h. Spleens were collected and splenocytes were restimulated in vitro for 72 h with 2.5 mg/ml of specific antigens. Antigen-specific
splenocyte proliferation was determined by thymidine incorporation and expressed as counts per minute. Each sample was examined in triplicate.
The results are shown as the mean6S.E. for five individual mice per group, representative of two independent experiments with similar results. #
p,0.0001 in comparison to control groups and * p,0.001 in comparison to data before infection as assessed by two-way ANOVA and Bonferroni’s
correction.
doi:10.1371/journal.pone.0005820.g003
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MREIVGCQAGQCGNQ, which corresponds to the b-tubulin of
L. major and L. donovani. Mass spectrometry of trypsin digested
LD72 was also identified as heat shock 70-related protein 1
mitochondrial precursor of L. major. Interestingly, the tryptic
digests of LD91 demonstrated the presence of b-tubulin of L.
major with 6 matched peptides.
Discussion
Over the past years major efforts have been dedicated to
develop novel vaccine candidates against leishmaniasis and
evaluate them in a variety of animal models. These efforts were
fueled by the publication of the L. major and L. infantum genome
and renewed interest in the field of leishmaniasis prophylaxis led to
the identification of a plethora of putative candidates for vaccine
development [2]. The vaccine components identified from genome
however, requires critical in vivo experimental evaluation to
establish their utility as candidate antigens. Although recombinant
proteins fulfill the key criteria, like consistent product quality and
cost-effectiveness, studies involving native proteins rather than
recombinant ones are needed, as the latter may lack similar
immunogenic characteristics [32]. Several vaccine candidates have
been identified and evaluated against different Leishmania spp.
However, in spite of homology between the different species and a
certain degree of cross protection, the need for identification of
new immunostimulatory molecules from individual species is still
Figure 4. Cytokine responses in BALB/c mice vaccinated with cationic liposomal antigens before and after challenge infection. Ten
days after the last vaccination and 3 months after challenge infection spleens were collected and splenocytes were restimulated in vitro with 2.5 mg/
ml of specific antigens. After 72 h supernatants were collected and assayed for IFN-c (A), IL-12 (B), IL-4 (C) and IL-10 (D) levels by ELISA. Each sample
was examined in duplicate. The results are shown as the mean6S.E. for five individual mice per group, representative of two independent
experiments with similar results. # p,0.0001 in comparison to control groups and * p,0.001 in comparison to data before infection as assessed by
two-way ANOVA and Bonferroni’s correction.
doi:10.1371/journal.pone.0005820.g004
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required. Additionally, the immune response that mediate
susceptibility or resistant to L. donovani infection differ significantly
from other species of Leshmania, especially L. major. In CL a
polarized Th1 response is sufficient for protection and a
concomitant Th2 abrogates even a strong Th1 function to favor
the disease progression. However, this Th1/Th2 dichotomy is
lacking in VL and a mixed response is essential for protection
[6,13,16,33]. But the immune parameters, which were required to
predict protection in VL, are still unresolved.
Although cell mediated immune responses are thought to play
important role in controlling leishmaniasis, ability to induce Th1
response might not be the only criteria to select vaccine targets
against VL [10,34]. Screening of expression libraries with sera
from infected animals and humans have been widely used to
identify most immunogenic novel vaccine antigens against
leishmaniasis [35]. As individuals with acute VL develop a
polyclonal B-cell response generating antibodies to a large number
of parasite antigens, a two-step library screening procedure first by
reactivity with patients’ sera followed by their ability to induce T
cell proliferation and IFN-c responses in immune mice might be
more useful [36]. Subsequently, antigens such as HASPB1 and A2
that induce strong protection against VL also showed serologic
reactivity with patients’ sera [37,38]. In our attempt to design a
vaccine against VL, we used a different approach and selected four
antigens that exhibited humoral reactivity with not only sera of
infected VL patients but also demonstrated persistence recognition
with cured sera. Moreover, PBMC from VL patients showed
proliferative response with an elevation in IFN-c and IL-12
production when stimulated with these antigens (unpublished
observation). Thus, in the absence of an efficient method to predict
protective antigens, we then critically evaluated the vaccine
efficacy of these antigens individually using an in vivo experimen-
tal mice model against L. donovani challenge infection.
Figure 5. Prechallenge antigen-specific IgG isotype responses
in BALB/c mice vaccinated with cationic liposomal antigens.
Ten days after last vaccination serum samples were collected and
assayed for antigen-specific IgG1 and IgG2a antibodies by ELISA. Each
sample was examined in duplicate. The results are shown as the mean
absorbance values6S.E. of five individual mice per group, representa-
tive of two independent experiments with similar results. * p,0.001 in
comparison to control groups as assessed by one-way ANOVA and
Tukey’s multiple comparison test.
doi:10.1371/journal.pone.0005820.g005
Figure 6. Correlates of immune responses and reduced parasite burdens in BALB/c mice vaccinated with cationic liposomal
antigens. Liver and spleen parasite burden after 3 months challenge infection with L. donovani promastigotes was tested for correlation with
antigen-specific prechallenge IFN-c, IL-12 and IL-4 responses. Magnitudes of the antigen-specific IFN-c, IL-12 and IL-4 production were inversely
correlated with the liver (A to C) and spleen (D to F) parasite burdens. Each symbol represents an individual animal from a vaccinated group. The p-
values were calculated for correlation efficiency and were considered significant at p,0.05. Spearman’s rank correlation coefficient values are
represented (r). Diagonal lines represent linear regression.
doi:10.1371/journal.pone.0005820.g006
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The findings in this report demonstrated that vaccination with
these polypeptides entrapped in cationic liposomes conferred
reduction in parasite burden in BALB/c mice against visceral
infection with L. donovani. Experiments performed herein also
demonstrated that stimulation of three cytokines, IFN-c, IL-12
and IL-4, before infection correlated with decreased parasite level.
All the vaccinated groups produced these three prechallenge
cytokines suggesting this quality of response is required for
successful vaccination against VL. We also observed a direct
correlation between the magnitude of the response and the level of
reduction in parasite load. Liposomal LD31 and LD51 immuni-
zation exihibited highest level of these three cytokines, reduced
parasite level in mice to the greatest degree. Immunization with
LD72 with moderate response led to a lower level of reduction
whereas liposomal LD91 immunization induced lowest level of
these cytokines and reduction of parasite load. Thus, not only the
quality but also the magnitudes of the prechallenge cytokine
responses were critical correlates of protection in VL. The findings
in this report with subunit vaccines also substantiate our earlier
observation with leishmanial antigens that an early mixed Th1/
Th2 response was required for success against VL [27,29].
Significantly elevated levels of IgG2a antibody along with
increased levels of IgG1 in vaccinated groups before infection
observed herein suggested a mixed Th1/Th2 cytokine profile.
Again the magnitude of the antibody response correlated with the
degree of reduction of parasite burden further supporting the
implication of this immune correlate.
The quality and magnitude of the immune response may be
regulated by the synergistic effect of these three cytokines. An IL-12
driven IFN-c-dependent Th1 response associated with protective
immunity, has a direct effect on the macrophage microbicidal
activity and other effector killing mechanisms [13]. IL-12 is known
to be involved not only in activation of NK cell but also
development of Th1 response and granuloma formation. Moreover,
it may have important role to establish cell-mediated immunity by
promoting the differentiation of Th1 cells from naive T cells and
also to maintain that immunity [39]. The essential role of IL-12 has
been confirmed in vivo by the treatment of mice with recombinant
IL-12 at the time of infection that shifted the immune response to
Th1 and prevented susceptibility to infection [40]. Additionally,
immunization with a combination of leishmanial antigens and IL-12
led to the development of a Th1 response and conferred protection
in BALB/c mice [41]. Another important candidate is IL-4, a
known Th2 cytokine. Previous reports have shown that IL-4 is
needed to drive Th1 differentiation [42], to maintain IFN-c
production [43] and to prime IL-12 production [44]. This suggests
that an early IL-4 may have a role in an initial induction of
protective immunity. The finding that IL-42/2 knockout mice were
more susceptible to L. donovani [18] and the reported beneficial role
of IL-4 in effective chemotherapy [45], suggest the protective ability
of this cytokine in VL. Thus, combinatorial effects of these cytokines
cause an additional paramount effect on magnitude of the
protective immune response. None of the protected groups
produced IL-10 after immunization, suggesting that IL-10 has no
role in protection. It is hypothesized that production of IL-10 may
be a prechallenge indicator for vaccine failure in CL [19], and thus
absence of IL-10 after immunization may also have beneficial role
in VL for protection.
As shown in this study LD31, LD51 and LD72 are protective
vaccine antigens, we had identified the proteins by MALDI-TOF
and N-terminal sequencing. The success of this approach was
made possible due to the availability of the entire sequence of L.
major and L. infantum genome. 31-kDa polypeptide was identified as
ATP synthase a chain of L. major. 51-kDa band was identified as b-
tubulin and 72-kDa was identified as heat shock 70-related protein
1 precursor of L. major. To our knowledge vaccine potentiality of
two of these antigens ATP synthase and b-tubulin have never been
evaluated against any form of leishmaniasis. L. major HSP70 was
evaluated as recombinant protein but failed to induce protection
against L. major [46].
ATP synthase complex subunits are functionally associated with
the membrane and thus can be potential targets for drugs,
diagnostic probes or vaccine components against Leishmania. ATP
synthase a subunit was already identified as immunogenic proteins
in Mycobacterium bovis [47] and intracellular pathogens like Brucella
[48] when probed with antisera from bovine and human patient.
The discrepancy in the observed and predicted molecular weight,
which seems to be 62-kDa, suggests a probable truncated form of
this protein. This phenomenon has been widely reported in the
proteomes of several Leishmania spp. as well as in Trypanosoma
[49,50]. Moreover, for membrane proteins often the gel molecular
weights do not correspond to the actual molecular weights based
on amino acid composition and bands may migrate anomalously
in SDS-PAGE [51]. Additionally, the difference in observed mass
from that predicted by the leishmanial genome, a common feature
reported in most proteomic analyses, may be the effect of protein
‘maturation’ events including co- or post-translational modifica-
tions (PTM). The observations from other studies of Leishmania
suggest that PTM is widely prevalent in this organism [49,50]. 51-
kDa band, identified as b-tubulin has previously been character-
ized as a T-cell stimulating antigen from Leishmania by CD4+ T cell
expression cloning [52]. Moreover, tubulin, has also been
identified as a vaccine candidate from a phage expression library
using sera of VL patients [53]. The 91-kDa polypeptide with a
homology with b-tubulin did not show immunogenicity and
protective immunity to that level as observed with 51-kDa antigen.
This 91-kDa band suggested that PTMs are the most likely cause
of variant forms of tubulin [49,50]. There are several different
Table 1. Proteins identified by MALDI-TOF/TOF mass spectrometry.
Band Protein name
Accession
Numbera
Matching
Peptides
Probability-based
Mowse score
% Sequence
coverage
LD31 ATP synthase a chain (L. major) 68223738 18 324 20
LD51 b-tubulin (L. major) 68224035 18 223 27
LD72 Heat shock 70-related protein 1 mitochondrial
precursor ( L. major)
57015345 11 71 18
LD91 b-tubulin (L. major) 68224035 6 57 14
aAccession number in NCBInr database.
doi:10.1371/journal.pone.0005820.t001
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types of modifications like methylation and mainly glycosylation
which include fucosylation and hexosylation, that are common to
b-tubulin [54]. Such multiple isoforms of tubulin caused by PTMs
were common in Leishmania and Trypanosoma [49,50]. As a result in
a proteomic study with T. brucei 84 gel spots were predicted to
match with b-tubulin [50]. Leishmania HSP70 are known to
potentiate a Thl-type response and can act as an adjuvant when
coconstruced with DNA vaccine [55]. Although immunization
with L. major HSP70 failed to induce protective responses in CL
[46], this antigen produce a Th1-type immune response, and was
identified as a probable vaccine candidate for canine VL [56]. The
microbial HSP70s have acquired special significance in immunity
since they have been shown to be potent activators of the innate
immune system via toll like receptor (TLR)-2 and TLR-4
signalling [57].
Although tubulin and HSP70 are highly conserved molecules,
there are still sufficient levels of heterogeneity between the parasite
and the host. In b-tubulin, despite 86% homology to its human
counterpart, the parasite tubulin-specific T cell reactivity was
observed in CL patients and no response was elicited by the
purified mammalian tubulin. Epitope mapping experiments also
showed that T cell reactivity was restricted to a small block of
nonconservative amino acid substitutions, suggesting subtle
sequence differences between the proteins of the invading
pathogen and the corresponding host homologs [52]. Similarly,
recombinant Leishmania HSP70 was effective in stimulating PBMC
from L. braziliensis-infected individuals to proliferate and produced
IFN-c [58]. But PBMC from mucosal patients were not stimulated
by recombinant human HSP70 to either proliferate or produce
cytokines despite the fact that Leishmania and human hsp70s share
72% homology [58]. In our study interestingly, during MALDI-
TOF data analysis these proteins were identified as protein of L.
major during the first search, when no restriction was applied to the
species of origin. Moreover, recognition of these proteins by the
sera from L. donovani infected patients indicated that there are
amino acid differences between Leishmania and host proteins that
are sufficiently distinct to allow recognition of the leishmanial
protein by the immune system.
In conclusion, our study depicts that optimal reduction of
parasite burden in VL requires stimulation of prechallenge IFN-c,
IL-12 and IL-4 following vaccination. Success against VL depends
on the synergistic effect of these three cytokines as well as their
magnitude, and may vary depending on the vaccines. Further,
identification of three successful vaccine antigens indicates that
these proteins in their recombinant form can potentially be
putative candidates of a subunit vaccine against VL.
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